Endofotonics (Singapore), a firm that has spun off from the National University of Singapore (NUS) has developed a system that it says will make performing molecular diagnosis in the body a reality. The company said that its IMDX system, an in-vivo molecular diagnostic device, which has yet to gain approval, could potentially enable objective cancer diagnosis to be available almost instantaneously during endoscopy.